These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 34970478)
1. Genetic Alteration Profiling of Chinese Lung Adenocarcinoma and Its Effect on Targeted Therapy Efficacy. Liu J; Xu WY; Ye M; Liu Z; Li C Front Oncol; 2021; 11():726547. PubMed ID: 34970478 [TBL] [Abstract][Full Text] [Related]
2. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer. Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q Front Oncol; 2021; 11():751106. PubMed ID: 35273907 [TBL] [Abstract][Full Text] [Related]
3. The landscape of actionable genomic alterations in lung adenocarcinomas in India. Sharma R; Kamireddy AP; Hussaini SM; Chatterjee S; Hasan Q; Jain J Front Genet; 2023; 14():1256756. PubMed ID: 38155717 [TBL] [Abstract][Full Text] [Related]
4. Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing. Zhou X; Xu X; Tian Z; Xu WY; Cui Y J Cancer Res Clin Oncol; 2020 Sep; 146(9):2277-2287. PubMed ID: 32572558 [TBL] [Abstract][Full Text] [Related]
5. The co-mutation of Zhang Y; Li S; Lyu Z; Cai J; Zheng N; Li Y; Xu T; Zeng H J Thorac Dis; 2022 Jan; 14(1):185-193. PubMed ID: 35242380 [TBL] [Abstract][Full Text] [Related]
6. Mutation Profile of Resected Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465 [TBL] [Abstract][Full Text] [Related]
7. Genomic features of Chinese small cell lung cancer. Liu J; Zhao Z; Wei S; Li B; Zhao Z BMC Med Genomics; 2022 May; 15(1):117. PubMed ID: 35596192 [TBL] [Abstract][Full Text] [Related]
8. Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation. Fernandes MGO; Jacob M; Martins N; Moura CS; Guimarães S; Reis JP; Justino A; Pina MJ; Cirnes L; Sousa C; Pinto J; Marques JA; Machado JC; Hespanhol V; Costa JL Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31443496 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile. Hou H; Zhu H; Zhao H; Yan W; Wang Y; Jiang M; Liu B; Liu D; Zhou N; Zhang C; Li P; Chang L; Guan Y; Wang Z; Zhang X; Li Z; Fang B; Zhang X Oncologist; 2018 Sep; 23(9):1008-1015. PubMed ID: 29700208 [TBL] [Abstract][Full Text] [Related]
10. Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients. Yang J; Li H; Li B; Li W; Guo Q; Hu L; Song Z; Zhou B Front Oncol; 2021; 11():647598. PubMed ID: 33898318 [TBL] [Abstract][Full Text] [Related]
11. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042 [TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy. Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552 [TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer. Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871 [TBL] [Abstract][Full Text] [Related]
14. Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). Zhong J; Li L; Wang Z; Bai H; Gai F; Duan J; Zhao J; Zhuo M; Wang Y; Wang S; Zang W; Wu M; An T; Rao G; Zhu G; Wang J J Thorac Oncol; 2017 Dec; 12(12):1766-1778. PubMed ID: 28818608 [TBL] [Abstract][Full Text] [Related]
15. Genomic Profiling and Clinicopathological Characteristics of Neuroendocrine Tumors of the Lung in East Asian Patients. Kim M; Chung YS; Kim KA; Shim HS In Vivo; 2020; 34(6):3375-3385. PubMed ID: 33144445 [TBL] [Abstract][Full Text] [Related]
16. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets. Veldore VH; Patil S; Satheesh CT; Shashidhara HP; Tejaswi R; Prabhudesai SA; Krishnamoorthy N; Hazarika D; Naik R; Rao RM; Ajai Kumar BS Indian J Cancer; 2015; 52(2):243-8. PubMed ID: 26853422 [TBL] [Abstract][Full Text] [Related]
17. Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer. Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S Anticancer Res; 2018 Oct; 38(10):5627-5634. PubMed ID: 30275180 [TBL] [Abstract][Full Text] [Related]
18. The prognostic value of tumor mutation burden in Jiao XD; He X; Qin BD; Liu K; Wu Y; Liu J; Hou T; Zang YS J Thorac Dis; 2019 Nov; 11(11):4507-4515. PubMed ID: 31903239 [TBL] [Abstract][Full Text] [Related]
19. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. Scheffler M; Ihle MA; Hein R; Merkelbach-Bruse S; Scheel AH; Siemanowski J; Brägelmann J; Kron A; Abedpour N; Ueckeroth F; Schüller M; Koleczko S; Michels S; Fassunke J; Pasternack H; Heydt C; Serke M; Fischer R; Schulte W; Gerigk U; Nogova L; Ko YD; Abdulla DSY; Riedel R; Kambartel KO; Lorenz J; Sauerland I; Randerath W; Kaminsky B; Hagmeyer L; Grohé C; Eisert A; Frank R; Gogl L; Schaepers C; Holzem A; Hellmich M; Thomas RK; Peifer M; Sos ML; Büttner R; Wolf J J Thorac Oncol; 2019 Apr; 14(4):606-616. PubMed ID: 30605727 [TBL] [Abstract][Full Text] [Related]
20. Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable Alterations. Yang J; Wang X; Lu J; Chen H; Zhao X; Gao C; Bai Y; Zhang Q; Fu X; Zhang X J Cancer; 2021; 12(17):5099-5105. PubMed ID: 34335926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]